Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246908 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Phase 2 study, sponsored by CeNeRx BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT01246908 is a Phase 2 study that has completed, run by CeNeRx BioPharma. The registered enrollment target is 360 participants.
The verdict
NCT01246908, a Phase 2 study, has completed, sponsored by CeNeRx BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
Interventions
- DRUG Placebo
- DRUG CX157 (TriRima)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246908
The ClinicalTrials.gov registry entry for NCT01246908 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CeNeRx BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01246908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246908 about?
NCT01246908 is a clinical study titled "Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression". The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
What is the current status of trial NCT01246908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2010-11. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01246908?
The interventions under investigation include: Placebo (DRUG), CX157 (TriRima) (DRUG).
Who is sponsoring clinical trial NCT01246908?
This trial is sponsored by CeNeRx BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.